Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
WORK Medical Technology Group Ltd. Class A (WOK)
USD2.01
+0.03 (+1.52%)
CN NASDAQ Healthcare Medical - Specialties
Address
No. 2 Tonghuinan Road 10158
Hangzhou, NY, CN
Hangzhou, NY, CN
CEO
Shuang Wu
Website
workmedtech.com
IPO
2024-08-23
CIK 1929783 ISIN KYG9767H1332
Description
WORK Medical Technology Group LTD, through with its subsidiaries, manufactures and sells medical consumables and devices in the People's Republic of China and internationally. The company offers medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, yankauer suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half masks; visualized prostatic dilatation catheters; and nebulizer kits, SPO2 sensors, nasogastric tubes, personal protective equipment, hygiene and skincare products, cleaners for household use, and non-powered air-purifying particle respirators. It also engages in the research and development of biological and medical technology; and sale of chemical products. The company serves hospitals, pharmacies, and medical institutions. It exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD2.01
+0.03 (+1.52%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
805.3K
Beta
1.26
Float Shares
5.8K
Free Float %
23.6%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -25.93% | -61.17% | -83.07% | -97.12% | -99.40% | -98.53% | -100.00% | -100.00% | -100.00% | -100.00% | -100.00% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
2.01
Quality scores
Altman Z-Score
0.53
Distress
Piotroski F-Score
6 / 9
Average
MOAT Score
1 / 10
No MOAT
Composite Rating
D+
Overall Score
1 / 5
Low
DCF Score
1 / 5
Low
ROE Score
1 / 5
Low
ROA Score
1 / 5
Low
D/E Score
2 / 5
Medium
P/E Score
1 / 5
Low
P/Book Score
1 / 5
Low
Operational MOAT
✗ Below peers
-
Revenue growth Medical - Specialties: +8.3%-14.4% Q3'25: +16.5% (vs Q3'23)
-
EPS growth Medical - Specialties: +10.1%-37.1% Q3'25: +4.7% (vs Q3'23)
-
FCF margin FCF growth · Medical - Specialties: +51.3%+53.2% Q3'25: +149.8% (vs Q3'23)
-
EBIT margin Medical - Specialties: +12.6%-5.9% Q3'25: -14.0% (vs Q3'23)
-
ROIC Medical - Specialties: +6.6%-2.5% Q3'25: -12.6% (vs Q3'23)
-
Share dilution Medical - Specialties: 0.0%+128.1% Q3'25: -17.1% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Medical - Specialties: -0.39×19.00× Q3'25: -10.20× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-06-18 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-06-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-10 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-09 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-03 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-02 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-06-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-26 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-19 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-18 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-15 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-14 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-13 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-12 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-11 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-08 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-07 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-06 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-05 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-04 | C | 2/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 5/5 |
| 2026-05-01 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-30 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-29 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-28 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-27 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-24 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-23 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-22 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-21 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-20 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-17 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
| 2026-04-16 | C | 2/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
3.31M
OE per share TTM
458.60
Owner's Yield
9,992.41%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
43.0%
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
2
Total invested
244.00
Insider transactions (90d)
12
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | LWY GROUP LTD | 6.25M | 42.83% | 6.25M | 6.25M | 6.25M | — | FI | VIRGIN ISLANDS, BRITISH | 2025-02-20 | ↗ |
| 2 | Trillium Trading, LLC | 220.0K | 18.00% | — | — | — | — | OO | NEW YORK | 2026-06-08 | ↗ |
| 3 | BIGGER CAPITAL FUND L P | — | 0.00% | — | — | — | — | PN | DELAWARE | 2025-10-14 | ↗ |
| 4 | Habbas Kelly Khalid | — | 0.00% | — | — | — | — | IN | UNITED STATES | 2026-06-16 | ↗ |
| 5 | L1 Capital Global Opportunities Master Fund, Ltd. | — | 0.00% | — | — | — | — | FI | CAYMAN ISLANDS | 2025-11-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
2
-1 vs prev Q
New positions
1
Closed positions
2
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | BANK OF AMERICA CORP /DE/ | — -262.0 (-100.0%) | — -19.0 (-100.0%) | 0.00% -0.002 pp | 0.00% +0.000 pp | USD— | 2 qtrs SOLD |
| 2 | CITADEL ADVISORS LLC | — -14.6K (-100.0%) | — -1.1K (-100.0%) | 0.00% -0.100 pp | 0.00% +0.000 pp | USD— | 5 qtrs SOLD |
| 3 | FEDERATION DES CAISSES DESJARDINS DU QUEBEC | — -200.0K (-100.0%) | — -15.0K (-100.0%) | 0.00% -1.368 pp | 0.00% 0.000 pp | USD— | 2 qtrs SOLD |
| 4 | SABBY MANAGEMENT, LLC | — -2.7M (-100.0%) | — -204.0K (-100.0%) | 0.00% -18.635 pp | 0.00% -0.236 pp | USD— | 2 qtrs SOLD |
| 5 | TWO SIGMA SECURITIES, LLC | — -48.8K (-100.0%) | — -3.7K (-100.0%) | 0.00% -0.334 pp | 0.00% -0.001 pp | USD— | 4 qtrs SOLD |
| 6 | UBS GROUP AG | — -3.3K (-100.0%) | — -248.0 (-100.0%) | 0.00% -0.023 pp | 0.00% +0.000 pp | USD— | 6 qtrs SOLD |
| 7 | VIRTU FINANCIAL LLC | — -311.8K (-100.0%) | — -23.0K (-100.0%) | 0.00% -2.133 pp | 0.00% -0.001 pp | USD— | 2 qtrs SOLD |
| 8 | XTX TOPCO LTD | — -38.1K (-100.0%) | — -2.9K (-100.0%) | 0.00% -0.261 pp | 0.00% 0.000 pp | USD— | 4 qtrs SOLD |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
2.67
Bullish
Ratio by volume
1.04
Neutral
Buys
8
Sells
3
Shares acquired
9.33M
Shares disposed
8.99M
Cash buys
8.00
Cash sales
3.00
Net activity
+346,055
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-16 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Common Stock | 2,904,567 | 0.06 | 168.5K | 391,456 | D | ↗ |
| 2026-06-15 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 268,927 | 0.10 | 25.5K | 3,296,023 | D | ↗ |
| 2026-06-12 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 48,108 | 0.08 | 3.8K | 3,027,096 | D | ↗ |
| 2026-06-11 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 2,029,327 | 0.09 | 188.7K | 2,978,988 | D | ↗ |
| 2026-06-10 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 1,765,384 | 0.10 | 174.8K | 949,661 | D | ↗ |
| 2026-06-09 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Common Stock | 3,463,022 | 0.11 | 363.6K | 0 | D | ↗ |
| 2026-06-08 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 2,261,118 | 0.11 | 239.7K | 2,647,299 | D | ↗ |
| 2026-06-05 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 54,529 | 0.09 | 5.1K | 386,181 | D | ↗ |
| 2026-06-04 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 1,370,008 | 0.11 | 143.9K | 331,652 | D | ↗ |
| 2026-06-01 | HRT FINANCIAL LP | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 351,959 | D | ↗ |
| 2026-05-29 | HRT FINANCIAL LP | 10% Owner | S-Sale | D | Common Stock | 2,619,607 | 0.10 | 262.0K | 0 | D | ↗ |
| 2026-05-28 | HRT FINANCIAL LP | 10% Owner | P-Purchase | A | Common Stock | 1,535,850 | 0.09 | 138.2K | 225,234 | D | ↗ |
| 2026-03-18 | Yu Baiming | Director / Officer | — | — | Class B Ordinary Share | 0 | 0.00 | — | 100,625 | I | ↗ |
| 2026-03-18 | Wu Zhenguo | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Wu Shuang Jarod | Director / Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Lin Qisheng | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Liang Ningfang | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2026-03-18 | Johnson Robert Brian | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
EBIT / Employee
-2.4K
Shares Outstanding
24.8K
Executive compensation
Executive compensation (annual)
Executive compensation not available.
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Baiming Yu | Chief Operating Officer & Director | — | male |
| Ningfang Liang | Chief Financial Officer | — | male |
| Shuang Wu | Chairman & Chief Executive Officer | — | male |
ESG Rating
ESG Score History MEDICAL - INSTRUMENTS & SUPPLIES
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for WOK
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
